Kuhnil to concentrate marketing on Gliadelwaper business.

Published: 2005-09-22 06:57:00
Updated: 2005-09-22 06:57:00
Kuhnil announced that the company would concentrate a whole effort to the market development of Gliadelwaper, a first choice of drug for the malignant glioma patients.

The company said Gliadelwaper is a locally implanting type of the radioactive therapeutic drugs into the tumor site by a sing...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.